

Tirzepatide

Dual GIP and GLP-1 receptor pharmacology

Author

Valentine Wibowo, Clinical Researcher

Medical review

dr. I Wayan Cahyadi Surya Distira Putra, MPH

Updated

23 August 2026 · Evidence cutoff 23 Aug 2026

ABSTRACT

Sustained co-agonism changes glucose-dependent endocrine signalling and energy intake through two defined incretin-receptor systems.

This monograph evaluates tirzepatide as a defined dual GIP/GLP-1 receptor agonist. It separates receptor pharmacology, human exposure, glycaemic and adiposity outcomes, body-composition change, tolerability and the durability problem after treatment withdrawal.

This monograph begins with the molecule and follows the causal chain through biochemistry, cellular mechanism, exposure and integrated physiology. Population studies enter only at the terminal stress-test: useful for the proposition actually tested, incapable of defining the molecule or replacing the causal model.

ESTABLISHED	UNRESOLVED
• Defined dual-receptor construct • Human PK established • Large phase 3 outcome datasets	• Individual body-composition response • Durability after discontinuation • Optimal phenotype-specific sequencing

EVIDENCE HIERARCHY

Mechanistic evidence is not a lower-grade substitute for population medicine. Physical constraints, biochemical measurements, historical and non-English records, exposure studies and clinical outcomes answer different questions. Controlled clinical trials test the complete implemented proposition; they cannot manufacture a missing identity, mechanism or exposure bridge.

I	Molecular identity and chemistry
II	Biochemistry and target architecture
III	Cells and ex-vivo tissues
IV	Animal and in-vivo pharmacology
V	Integrated physiology and translation
VI	Human PK and observational signal
VII	Controlled clinical trials

CONTENTS

01 Action ledger

- 02 Methods and coverage
- 03 Evidence atlas
- 04 Molecular dossier: the entity before the outcome
- 05 Historical and international corpus
- 06 Incretin lineage: Mature physiology, construct-specific pharmacology
- 07 2021-2026: Reproducible human programme across phenotypes
- 08 Mechanistic calculus — CONSTRAINED: Intermediate variables are not interchangeable
- 09 Mechanistic calculus — MEASURED: Composition resolves the weight equation
- 10 Mechanistic calculus — MEASURED: Withdrawal identifies exposure as causal
- 11 Causal architecture: Dual agonism is a molecular property
- 12 Causal architecture: Endocrine signalling is glucose-contextual
- 13 Causal architecture: Albumin-associated persistence changes the experiment
- 14 Causal architecture: Body composition adjudicates biological quality
- 15 Molecular identity and entity resolution
- 16 Biochemical mechanism and target architecture
- 17 In-vivo pharmacology and exposure
- 18 Integrated physiology and individual terrain
- 19 Terminal human stress-test
- 20 Counterevidence and causal boundaries
- 21 Scientific conclusion
- 22 Dual-receptor molecular pharmacology
- 23 Human exposure and escalation
- 24 Weight and body-composition outcomes
- 25 Translation across populations
- 26 Boundaries and durability
- 27 Durability, comorbidity and comparative trials
- 28 Falsification map
- 29 Research agenda
- 30 Cited primary evidence corpus

ACTION LEDGER

Describe the action before judging its value.

Benefit is a downstream clinical judgement. The scientific object is the action itself: what moves, under which exposure, in which biological state, and where the inference stops.

01 Attributed biochemical action	Sustained co-agonism changes glucose-dependent endocrine signalling and energy intake through two defined incretin-receptor systems.
02 Exposure and reachability	Population pharmacokinetics support once-weekly dosing and characterise exposure in humans. Clinical translation still depends on escalation, co-therapy and the individual metabolic phenotype.
03 Physiological direction is contextual	The relevant physiological state is not weight in isolation. Appetite suppression, glucose-dependent insulin secretion, gastric kinetics, adipose loss, lean-tissue preservation, hydration and functional capacity interact. A favourable response requires improvement in metabolic load without an unacceptable loss of nutrition, muscle or performance.
04 Individual adjudication boundary	Individual partitioning of fat, lean tissue, appetite adaptation and post-withdrawal physiology. Population-average weight loss cannot be equated with preserved muscle, durable metabolic restoration or a universal indication.

METHODS AND COVERAGE

A reproducible boundary, not an implied exhaustive review.

This curated mechanistic monograph uses primary indexed records and reference-chaining. It does not claim systematic-review completeness. Absence of a retrieved result is not evidence that an effect is absent.

SEARCH SURFACE	PubMed/MEDLINE primary records, Russian-language indexed abstracts, and reference-chaining for entity-defining, historical and translational studies. Language, geography, regulatory status and journal fashion are not evidence grades.
QUERY FRAME	tirzepatide · GIP receptor · GLP-1 receptor · SURMOUNT · obesity · body composition · type 2 diabetes
EVIDENCE CUTOFF	23 August 2026
ENTITY EXCLUSION	The molecule is not interchangeable with native GIP, a GLP-1-only agonist or a compounded mixture. Receptor bias, albumin-associated persistence and dose history belong to the construct.
TRACEABILITY	13 extended claim units plus 2 historical records and 3 mechanistic-calculus records; 11 cited records in the complete corpus.
INTERPRETIVE RULE	Identity → physical constraint → measured reaction or binding → reachable exposure → system response → outcome. Statistical significance does not manufacture mechanism; mechanistic plausibility does not manufacture a patient outcome.

EVIDENCE ATLAS

Every claim keeps its experimental address.

13 claim units are mapped to evidentiary layer, experimental frame and source records. The layer describes the question answered; it is not a popularity score.

LAYER	EXPERIMENTAL FRAME	FINDING AND BOUNDARY	SOURCES
VI Human exposure or signal	Dual-receptor molecular pharmacology · claim 1	Tirzepatide is a single long-acting peptide with activity at the GIP and GLP-1 receptors. The clinical phenotype emerges from integrated receptor signalling, sustained exposure and reduced energy intake. It cannot be reconstructed by adding the separate literature of native GIP and a conventional GLP-1 agonist.	[1][3]
II/V Mechanism and physiological translation	Dual-receptor molecular pharmacology · claim 2	GIP and GLP-1 signalling converge on glucose-dependent insulin secretion while differing in tissue distribution and contextual effects. Appetite, gastric physiology, adipose biology and glycaemic control are therefore connected but non-identical outcome domains. A change in HbA1c cannot be used as a proxy for preserved lean mass or functional recovery.	[1][3]
VI Human exposure or signal	Human exposure and escalation · claim 1	Population pharmacokinetic work supports once-weekly administration and describes prolonged exposure. Clinical interpretation still requires the actual escalation schedule, missed doses, co-medication and gastrointestinal tolerance because those variables determine achieved exposure and retention on therapy.	[3]
VI Human exposure or signal	Human exposure and escalation · claim 2	The molecule has a mature human programme, but maturity does not make every use interchangeable. Diabetes, obesity, obstructive sleep apnoea and other studied phenotypes differ in baseline risk, endpoints and concomitant care. Evidence belongs to the population and outcome studied.	[1][4]
VII Controlled human proposition	Weight and body-composition outcomes · claim 1	SURMOUNT-1 randomised 2,539 adults with obesity or overweight. Mean weight change at 72 weeks was -15.0%, -19.5% and -20.9% with 5, 10 and 15 mg, compared with -3.1% with placebo. The scale signal is large and dose related, but remains an average under a structured trial programme.	[1]

LAYER	EXPERIMENTAL FRAME	FINDING AND BOUNDARY	SOURCES
VI Human exposure or signal	Weight and body-composition outcomes · claim 2	The DXA substudy adds a necessary compositional layer. In 160 participants with evaluable scans, pooled tirzepatide groups lost 33.9% fat mass and 10.9% lean mass; approximately 75% of weight lost was fat and 25% lean mass on average. The average ratio does not reveal who lost disproportionate lean tissue or function.	[2]
VII Controlled human proposition	Translation across populations · claim 1	SURMOUNT-CN provides a separate randomised test in Chinese adults. At week 52, mean weight change was -13.6% with 10 mg and -17.5% with 15 mg versus -2.3% with placebo. This supports reproducibility across a different population while also demonstrating that effect size is context dependent rather than a fixed property of the molecule.	[4]
IV Integrated in-vivo model	Translation across populations · claim 2	Clinical translation must preserve nutrition, resistance stimulus, hydration and management of gastrointestinal symptoms. These are not lifestyle footnotes: they modify the biological meaning of weight loss and determine whether adiposity reduction is accompanied by preserved strength and metabolic resilience.	[1][2][4]
VII Controlled human proposition	Boundaries and durability · claim 1	Gastrointestinal adverse events and discontinuations cluster around escalation. Gallbladder events, pancreatitis signals, severe dehydration and changes in glycaemia are outcome domains requiring direct surveillance. Absence of a signal in an average trial participant does not erase risk in a patient with a different baseline terrain.	[1][4]
II/V Mechanism and physiological translation	Boundaries and durability · claim 2	The major unresolved scientific question is not whether tirzepatide can reduce weight during treatment; that is established. It is how the response is maintained, what happens to appetite and body composition after withdrawal, and which biological or behavioural architecture can preserve benefit without indefinite assumption.	[1][2]
VII Controlled human proposition	Durability, comorbidity and comparative trials · claim 1	SURMOUNT-4 directly tested withdrawal rather than assuming durability. Participants who continued tirzepatide maintained and extended weight reduction, whereas those switched to placebo regained substantial weight. This identifies continued exposure as a causal part of the studied outcome; it does not prove that every patient requires the same duration or that post-withdrawal biology is immutable.	[5]

LAYER	EXPERIMENTAL FRAME	FINDING AND BOUNDARY	SOURCES
VIIControlled human proposition	Durability, comorbidity and comparative trials · claim 2	Controlled programmes in obstructive sleep apnoea and metabolic dysfunction-associated steatohepatitis test distinct propositions with disease-specific endpoints. Their positive signals cannot be collapsed into a generic wellness claim, but they demonstrate that the molecule’s consequences extend beyond scale weight when the relevant physiology is measured directly.	[6][7]
VIIControlled human proposition	Durability, comorbidity and comparative trials · claim 3	SURPASS-1, SURPASS-2 and SURPASS-5 establish glycaemic efficacy across monotherapy, active-comparator and basal-insulin settings; SURMOUNT-2 separately tests weight reduction in adults with type 2 diabetes. Together they strengthen reproducibility while showing why background treatment, comparator and phenotype must remain attached to each effect estimate.	[8][9][10][11]

SECTION 01

Molecular dossier: the entity before the outcome

ENTITY — One acylated dual-receptor peptide construct

BIOCHEMICAL CLASS — Long-acting GIPR/GLP-1R co-agonist

PRIMARY SYSTEM — GIPR · GLP-1R

IDENTITY BOUNDARY — The molecule is not interchangeable with native GIP, a GLP-1-only agonist or a compounded mixture. Receptor bias, albumin-associated persistence and dose history belong to the construct.

SECTION 02

Historical and international corpus

Tirzepatide is a modern dual agonist, not a century-old entity. Its mechanism inherits questions from decades of incretin biology, while its efficacy and pharmacokinetics belong to the exact peptide.

The direct human corpus is mature. The remaining mechanistic task is to separate receptor contribution, energy-intake mediation, tissue-specific effects and consequences of continuing or withdrawing exposure.

SECTION 03

Incretin lineage: Mature physiology, construct-specific pharmacology

GIP and GLP-1 physiology supplied the design space. Tirzepatide nonetheless creates its own balance of receptor activity, albumin-associated persistence and repeated weekly exposure; native hormones do not predict that complete state.[3]

SECTION 04

2021-2026: Reproducible human programme across phenotypes

Monotherapy, active-comparator, basal-insulin, obesity, withdrawal, sleep-apnoea and liver programmes test different propositions. Their value lies in triangulation, not in collapsing every endpoint into one generic claim.[1][4][5][6][7][8][9][10][11]

SECTION 05

Mechanistic calculus — CONSTRAINED: Intermediate variables are not interchangeable

HbA1c, scale weight, fat mass, lean mass, muscle function and appetite are distinct state variables. Movement in one cannot mathematically substitute for an unmeasured change in another.[1][2]

SECTION 06

Mechanistic calculus — MEASURED: Composition resolves the weight equation

The DXA substudy indicates that average lost mass was predominantly fat but included lean mass. That partition is a population mean and must not be imposed on an individual without longitudinal composition and function measurements.[2]

SECTION 07

Mechanistic calculus — MEASURED: Withdrawal identifies exposure as causal

Regain after randomised withdrawal demonstrates that continuing pharmacological exposure was part of the maintained trial phenotype. It does not prove a universal lifetime duration; it localises the causal dependency in that protocol.[5]

SECTION 08

Causal architecture: Dual agonism is a molecular property

Tirzepatide carries GIPR and GLP-1R activity in one long-acting construct. Its phenotype cannot be reconstructed by adding the independent literatures of native GIP and a conventional GLP-1 agonist because sequence, signalling bias, receptor occupancy and residence time differ.[1][3]

SECTION 09

Causal architecture: Endocrine signalling is glucose-contextual

Both receptor systems can amplify glucose-dependent insulin secretion, while GLP-1R signalling also affects glucagon, appetite and gastric physiology. The same dose can therefore produce different glycaemic and nutritional consequences according to baseline insulin reserve, food intake and concomitant treatment.[1][3]

SECTION 10

Causal architecture: Albumin-associated persistence changes the experiment

Prolonged exposure supports weekly administration and produces sustained rather than meal-limited receptor stimulation. Escalation, missed doses and gastrointestinal tolerance are causal exposure variables; a maintenance-dose label without its concentration-time history is incomplete pharmacology.[3]

SECTION 11

Causal architecture: Body composition adjudicates biological quality

Adiposity reduction and lean-mass loss can occur within the same average response. DXA and functional endpoints help determine whether reduced energy stores coexist with preserved contractile capacity, protein adequacy and metabolic resilience.[1][2]

SECTION 12

Molecular identity and entity resolution

Tirzepatide is a long-acting dual GIP/GLP-1 receptor agonist with a mature human development programme. Results belong to the exact construct, formulation and exposure studied.

SECTION 13

Biochemical mechanism and target architecture

Integrated GIP and GLP-1 receptor signalling changes appetite, glucose-dependent insulin secretion, gastric physiology and energy intake. Dose, adherence, diet, resistance stimulus, sleep and concomitant therapy remain causal parts of the observed trajectory.

SECTION 14

In-vivo pharmacology and exposure

Population pharmacokinetics support once-weekly dosing and characterise exposure in humans. Clinical translation still depends on escalation, co-therapy and the individual metabolic phenotype.

SECTION 15

Integrated physiology and individual terrain

The relevant physiological state is not weight in isolation. Appetite suppression, glucose-dependent insulin secretion, gastric kinetics, adipose loss, lean-tissue preservation, hydration and functional capacity interact. A favourable response requires improvement in metabolic load without an unacceptable loss of nutrition, muscle or performance.

SECTION 16

Terminal human stress-test

SURMOUNT-1 randomised 2,539 adults. Mean weight change at week 72 was -15.0%, -19.5% and -20.9% with 5, 10 and 15 mg, versus -3.1% with placebo. Body-composition analysis estimated that approximately 75% of weight lost was fat mass and 25% lean mass on average.

SECTION 17

Counterevidence and causal boundaries

Gastrointestinal adverse events and treatment discontinuation were more frequent during active treatment, particularly during escalation. A favourable average does not guarantee preserved function, adequate nutrition or an acceptable response for an individual.

SECTION 18

Scientific conclusion

Tirzepatide combines strong mechanistic definition, human pharmacology and controlled clinical validation. Successful interpretation requires adiposity or glycaemic improvement without unacceptable nutritional, functional or safety cost.

SECTION 19

Dual-receptor molecular pharmacology

Tirzepatide is a single long-acting peptide with activity at the GIP and GLP-1 receptors. The clinical phenotype emerges from integrated receptor signalling, sustained exposure and reduced energy intake. It cannot be reconstructed by adding the separate literature of native GIP and a conventional GLP-1 agonist.[1][3]

GIP and GLP-1 signalling converge on glucose-dependent insulin secretion while differing in tissue distribution and contextual effects. Appetite, gastric physiology, adipose biology and glycaemic control are therefore connected but non-identical outcome domains. A change in HbA1c cannot be used as a proxy for preserved lean mass or functional recovery.[1][3]

SECTION 20

Human exposure and escalation

Population pharmacokinetic work supports once-weekly administration and describes prolonged exposure. Clinical interpretation still requires the actual escalation schedule, missed doses, co-medication and gastrointestinal tolerance because those variables determine achieved exposure and retention on therapy.[3]

The molecule has a mature human programme, but maturity does not make every use interchangeable. Diabetes, obesity, obstructive sleep apnoea and other studied phenotypes differ in baseline risk, endpoints and concomitant care. Evidence belongs to the population and outcome studied.[1][4]

SECTION 21

Weight and body-composition outcomes

SURMOUNT-1 randomised 2,539 adults with obesity or overweight. Mean weight change at 72 weeks was -15.0%, -19.5% and -20.9% with 5, 10 and 15 mg, compared with -3.1% with placebo. The scale signal is large and dose related, but remains an average under a structured trial programme.[1]

The DXA substudy adds a necessary compositional layer. In 160 participants with evaluable scans, pooled tirzepatide groups lost 33.9% fat mass and 10.9% lean mass; approximately 75% of weight lost was fat and 25% lean mass on average. The average ratio does not reveal who lost disproportionate lean tissue or function.[2]

SECTION 22

Translation across populations

SURMOUNT-CN provides a separate randomised test in Chinese adults. At week 52, mean weight change was -13.6% with 10 mg and -17.5% with 15 mg versus -2.3% with placebo. This supports reproducibility across a different population while also demonstrating that effect size is context dependent rather than a fixed property of the molecule.[4]

Clinical translation must preserve nutrition, resistance stimulus, hydration and management of gastrointestinal symptoms. These are not lifestyle footnotes: they modify the biological meaning of weight loss and determine whether adiposity reduction is accompanied by preserved strength and metabolic resilience.[1][2][4]

SECTION 23

Boundaries and durability

Gastrointestinal adverse events and discontinuations cluster around escalation. Gallbladder events, pancreatitis signals, severe dehydration and changes in glycaemia are outcome domains requiring direct surveillance. Absence of a signal in an average trial participant does not erase risk in a patient with a different baseline terrain.[1][4]

The major unresolved scientific question is not whether tirzepatide can reduce weight during treatment; that is established. It is how the response is maintained, what happens to appetite and body composition after withdrawal, and which biological or behavioural architecture can preserve benefit without indefinite assumption.[1][2]

SECTION 24

Durability, comorbidity and comparative trials

SURMOUNT-4 directly tested withdrawal rather than assuming durability. Participants who continued tirzepatide maintained and extended weight reduction, whereas those switched to placebo regained substantial weight. This identifies continued exposure as a causal part of the studied outcome; it does not prove that every patient requires the same duration or that post-withdrawal biology is immutable.[5]

Controlled programmes in obstructive sleep apnoea and metabolic dysfunction-associated steatohepatitis test distinct propositions with disease-specific endpoints. Their positive signals cannot be collapsed into a generic wellness claim, but they demonstrate that the molecule's consequences extend beyond scale weight when the relevant physiology is measured directly.[6][7]

SURPASS-1, SURPASS-2 and SURPASS-5 establish glycaemic efficacy across monotherapy, active-comparator and basal-insulin settings; SURMOUNT-2 separately tests weight reduction in adults with type 2 diabetes. Together they strengthen reproducibility while showing why background treatment, comparator and phenotype must remain attached to each effect estimate.[8][9][10][11]

SECTION 25

Falsification map

Absence of exposure-related glycaemic or appetite effects would challenge effective dual-receptor engagement.

A response dominated by lean-tissue or functional loss would falsify a broadly favourable body-composition claim.

Rapid reversal after withdrawal would constrain claims of durable metabolic restoration.

RESEARCH AGENDA

What would materially change the conclusion?

- 01 Long-term cardiovascular and renal outcome interpretation by phenotype
- 02 Post-withdrawal appetite and body-composition trajectories
- 03 Predictors of disproportionate lean-mass loss
- 04 Nutrition and resistance-training interaction studies
- 05 Comparative receptor-level studies against single GLP-1 agonism

CITED PRIMARY EVIDENCE CORPUS

11 source records

This corpus documents the claims made in this monograph; it is not presented as an exhaustive systematic-review search.

Jastreboff et al. N Engl J Med. 2022;387:205-216. · PMID 35658024	Look et al. Diabetes Obes Metab. 2025;27:2720-2729. · PMID 39996356
Schneck & Urva. CPT Pharmacometrics Syst Pharmacol. 2024. · PMID 38356317	Zhao et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: SURMOUNT-CN. JAMA. 2024. · PMID 38819983
Aronne et al. JAMA. 2024;331:38-48. SURMOUNT-4. · PMID 38078870	Malhotra et al. N Engl J Med. 2024;391:1193-1205. SURMOUNT-OSA. · PMID 38912654
Loomba et al. N Engl J Med. 2024;391:299-310. SYNERGY-NASH. · PMID 38856224	Frías et al. N Engl J Med. 2021;385:503-515. SURPASS-2. · PMID 34170647
Garvey et al. Lancet. 2023;402:613-626. SURMOUNT-2. · PMID 37385275	Rosenstock et al. Lancet. 2021;398:143-155. SURPASS-1. · PMID 34186022
Dahl et al. JAMA. 2022;327:534-545. SURPASS-5. · PMID 35133415	

AUTHORSHIP AND ACCOUNTABILITY

Valentine Wibowo performed the conceptualisation, evidence synthesis, scientific interpretation and drafting. dr. I Wayan Cahyadi Surya Distira Putra, MPH completed medical review and approved the publication. Internal medical review is not represented as independent journal peer review.

No new patient data or human research were undertaken. The author and reviewer declare no personal financial competing interests. Clinic Terrain and Klinik Pratama Cepat Sehat provide clinical services; that institutional relationship is disclosed.